Combined chemotherapy and allogeneic human VÎ³9VÎ´2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells <i>in vivo</i>.

Joalland, Noémie; Lafrance, Laura; Oullier, Thibauld; Marionneau-Lambot, Séverine; Loussouarn, Delphine; Jarry, Ulrich; Scotet, Emmanuel

Combined chemotherapy and allogeneic human VÎ³9VÎ´2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo.

Joalland, Noémie; Lafrance, Laura; Oullier, Thibauld; Marionneau-Lambot, Séverine; Loussouarn, Delphine; Jarry, Ulrich; Scotet, Emmanuel.

Afiliação

Joalland N; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Lafrance L; LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
Oullier T; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Marionneau-Lambot S; LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
Loussouarn D; Cancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
Jarry U; Cancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
Scotet E; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

Oncoimmunology ; 8(11): e1649971, 2019.

Article em En | MEDLINE | ID: mdl-31646097

Palavras-chave

Human VÎ³9VÎ´2 T lymphocytes; chemotherapy; epithelial ovarian cancer; immunotherapy; orthotopic xenograft mouse model; zoledronate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article